The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
The target reach is of more than 30 million young people and caregivers across 21 countries
Global specialty pipeline accelerates growth
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
Highlighting KEYTRUDA & expanding cancer pipeline
Nearly one in five women worldwide are now living with obesity
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
Subscribe To Our Newsletter & Stay Updated
